Ziconotide in severe, drug-resistant cancer pain. preliminary experience
The Author reports the case of ziconotide intrathecal treatment in three terminal cancer patients, with nociceptive and neuropathic pain, unresponsive to the treatment with intrathecal opioid and adjuvant drugs. An external pump for continuous subarachnoid infusion was implanted to the three pati...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Publiediting
2008-12-01
|
| Series: | Pathos |
| Subjects: | |
| Online Access: | http://www.pathos-journal.com/doc/2008_4_Casi_Lavano.pdf |
| Summary: | The Author reports the case of ziconotide intrathecal treatment
in three terminal cancer patients, with nociceptive and neuropathic
pain, unresponsive to the treatment with intrathecal opioid and
adjuvant drugs. An external pump for continuous subarachnoid infusion was implanted to the three patients. The initial dose was 2,4 mcg/die, with increments of 1,2 mcg/die every three days till the maximum dose of 4,8 mcg/die in two patients (survival 61 and 45 days) and 7,2 mcg/die in a patient (survival 52 days). VAS reduction was 50% in the fi rst patient, of 57% in the second one and 70% in the third one. In one case, at the dose of 4,8 mcg/die,
the treatment was associated with important collateral effects,
that requested the temporary suspension of the drug. |
|---|---|
| ISSN: | 1593-2354 1593-2354 |